Boston Scientific is initiating a global restructuring programme in 2026 aimed at driving sustained cost efficiencies and supporting growth, a move that will result in job cuts across the company. The restructuring activities are expected to be largely completed by the end of 2029.
Estimated total cost of the restructuring plan, with $600M-$700M in future cash outlays.
The plan is expected to reduce annual pre-tax expenses by approximately $500 million as benefits are realized. Up to $300 million of the total cost will be incurred due to terminations, while up to $350 million relates to transferring product manufacturing lines between facilities, and up to $150 million is for other associated costs.
Boston Scientific's shares on the New York Stock Exchange rose by 2.85% to $45.51 at market close on July 27, up from $44.60. The company has a market cap of $67.64 billion. Shares rose further by 2% at market open on July 28.
The company is set to release its Q2 results on July 29. In Q1, Boston reported revenue of around $5.2 billion, broadly in line with the same quarter in 2025. Boston also elected to trim its full-year outlook by 2% at the top end. CEO Mike Mahoney cited 'ongoing competitive dynamics' for the trimmed outlook.
Ongoing competitive dynamics